source
- Sensorion drops OTOF gene therapy to focus on GJB2-targeted hearing loss candidate after Regeneron approvalSensorion said it is ending development of its gene therapy SENS-501 for OTOF related hearing loss after a strategic review. The review concluded that the competitive landscape had changed signific…
- AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight lossAstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…